Status:

UNKNOWN

Proviral DNA as a Target for HIV-1 Resistance Analysis

Lead Sponsor:

University of Chile

Collaborating Sponsors:

ViiV Healthcare

Conditions:

HIV/AIDS

HIV Infections

Eligibility:

All Genders

18-99 years

Brief Summary

In summary, in this project the investigators propose to study the proviral DNA genotyping to implement a lower cost and wider than the commercial systems currently in use, in order to analyze all HIV...

Detailed Description

A prospective longitudinal observational study, the objective is to observe and describe the prevalence of INRT, INNRT, Protease and INIS mutations detected by proviral DNA in patients with virologic ...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of HIV
  • viral load \<1.000 copies/mL
  • under antiretroviral tratment

Exclusion

  • HIV negative
  • viral load \>1.000 copies/mL

Key Trial Info

Start Date :

October 15 2018

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2022

Estimated Enrollment :

1200 Patients enrolled

Trial Details

Trial ID

NCT04088916

Start Date

October 15 2018

End Date

December 31 2022

Last Update

September 17 2019

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Immunology, HIV and Allergy Section

Santiago, Santiago Metropolitan, Chile

2

Molecular Medicine Laboratory

Santiago, Santiago Metropolitan, Chile

Proviral DNA as a Target for HIV-1 Resistance Analysis | DecenTrialz